Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) hit a new 52-week high on Monday . The company traded as high as $29.00 and last traded at $26.98, with a volume of 379019 shares. The stock had previously closed at $28.69.
Gemini Therapeutics Price Performance
The company has a market capitalization of $1.17 billion, a P/E ratio of -27.00 and a beta of -0.12. The stock’s 50 day simple moving average is $53.77 and its two-hundred day simple moving average is $54.92.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- High-Yield Texas Instruments Could Hit New Highs Soon
- Do ETFs Pay Dividends? What You Need to Know
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
